Abstract
Dengue fever (DF) and dengue hemorrhagic fever (DHF) are important arthropod-borne viral diseases. Each year, there are ~50 million dengue infections and ~500,000 individuals are hospitalized with DHF, mainly in Southeast Asia. Dengue in India has dramatically expanded over the last few decades, with rapidly changing epidemiology. The first major DHF outbreak in the entire nation occurred in 1996 by dengue virus serotype 2, and after a gap of almost a decade, the country faced yet another DF outbreak in the year 2003 by dengue virus serotype 3. A dramatic increase in the number and frequency of outbreaks followed, and, at present, in most of the states of India, dengue is almost endemic. At present, all the four serotypes are seen in circulation, but the predominant serotype keeps changing. Despite this trend, surveillance, reporting, and diagnosis of dengue remain largely passive in India. More active community-based epidemiological studies with intensive vector control and initiatives for dengue vaccine development should be geared up to control the spread of dengue in India. We review here the factors that may have contributed to the changing epidemiology of dengue in India.
Introduction
Dengue virus infection is a major, growing public health problem with an estimated 2.5 billion people at risk of infection. Dengue viruses can cause a wide variety of clinical illnesses ranging from mildly symptomatic dengue fever (DF) to more dangerous clinical conditions with capillary leakage syndrome such as dengue shock syndrome (DSS) and dengue hemorrhagic fever (DHF).Citation1 Globally, dengue virus transmission has expanded in recent years, and all four dengue virus serotypes are now circulating in Asia, Africa, and the Americas.Citation1
Dengue in India has dramatically expanded over the last few decades, with rapidly changing epidemiology.Citation2–Citation4 Although the first mention of occurrence of dengue in India is said to be in 1780, the first confirmed outbreak occurred in Kolkata in 1963–1964.Citation5–Citation7 It took almost 30 years for dengue to eventually spread throughout the entire country, resulting in the first major nationwide outbreak of DHF in the year 1996.Citation8–Citation11 Following this, gradual dengue virus expansion started in the entire nation, and northern parts of India faced yet another outbreak in 2003.Citation12,Citation13 A dramatic increase in the number and frequency of outbreaks followed, and, at present, in most of the states of India, all four serotypes are prevalent.Citation2,Citation4,Citation14 This paper, therefore, reviews current perspectives of the spread of dengue in India and its implications.
Dengue virus
Dengue virus belongs to the genus Flavivirus in the family Flaviviridae. It is a positive-stranded encapsulated ribonucleic acid (RNA) virus that is composed of three structural protein genes that encode the nucleocapsid or core protein, a membrane-associated protein, an enveloped glycoprotein, and seven nonstructural proteins. It is transmitted mainly by the Aedes aegypti mosquito and also by the Aedes albopictus mosquito. There are four antigenetically related but distinct serotypes of the dengue virus: DENV-1, DENV-2, DENV-3, and DENV-4. Each serotype has several subtypes or genotypes. DENV-1 has three, DENV-2 has two, and DENV-3 and DENV-4 each have four. In humans, one serotype produces lifelong immunity against reinfection but only temporary and partial immunity against the other serotypes.Citation15 Each serotype has unique characteristics and can present with severe manifestations in a particular population depending upon its interaction with the host response.
Changing epidemiology in India
The Indian encounter with dengue is interesting and intriguing. The epidemiology of dengue in India is very complex and ever changing. Though the first reported occurrence of dengue fever in India was in 1946, there were no major outbreaks in the country for almost 20 years, until a major epidemic occurred in 1963–1964 in Kolkata.Citation16–Citation18 It gradually spread to involve North India in 1967–1968 and also South India.Citation19,Citation20 All four serotypes of the virus were reported from South India.Citation21 Again, after almost three decades of very low incidence, the first major outbreak of DF/DHF occurred in Delhi in 1996 where 10,252 cases and 423 deaths were reported.Citation10 This outbreak was caused by DENV-2, genotype IV strain of the virus.Citation22 Similar strains of the DENV-2 were reported from central India (Gwalior) and southern India, indicating that the predominant circulating strain in India that time was DENV-2.Citation23 In the post-epidemic period in Delhi in 1997, DENV-1 was also seen in circulation.Citation24
Dengue started spreading in the interior of India with reported cases from western and southern India. Awareness of this disease and diagnostic modalities also grew, and more frequent reporting of cases occurred. In northern parts of India, the number of reported DF/DHF cases increased, probably because, as now, the health authorities of the country became more vigilant, and timely reporting of all cases was initiated. Serotypes of the virus kept changing from year to year, and each time that either the serotype showed a change or the genotype showed a change, increased cases were seen in that area.Citation13 By 1996–2003, almost all the four serotypes were reported, and frequency of the outbreaks also increased in the population ().Citation25–Citation33
In 2003, another major outbreak engulfed northern and central India (particularly in Delhi and Gwalior), and at this time, all four serotypes were seen in circulation for the first time in Delhi.Citation2,Citation14 The major serotype reported both from Delhi and Gwalior was DENV- 3.Citation2,Citation13 The reemergence of this epidemic strain of DENV-3 in Delhi in 2003 and its persistence in subsequent years marked a changing trend in DENV circulation in India. This again showed the shift in the epidemiology of dengue virus in India. Subsequently, recurring outbreaks of DF/DHF were reported in the years 2005–2008 from various states in India, namely Andhra Pradesh, Delhi, Goa, Haryana, Gujarat, Karnataka, Kerala, Maharashtra, Rajasthan, Uttar Pradesh, Pondicherry, Punjab, Tamil Nadu, West Bengal, and Chandigarh.Citation34 India reported a total of 28,292 cases and 110 deaths in 2010, the highest number of cases and number deaths in a single year in the country in the previous two decades. In Delhi, following predominance of the DENV-3 strain from 2003–2006, DENV-1 circulation was seen.Citation32 A shift in the age group involvement from children to young adults was also noticed in several studies from India.Citation2,Citation12 Concurrent infection with multiple serotypes of dengue was also seen.Citation35,Citation36 Thus, it is evident that now in India there is a definite increase in the frequency and number of outbreaks along with co-circulation of all four serotypes, hinting toward hyperendemicity of dengue in India.
Burden of disease in India
According to the World Health Organization, the incidence of dengue globally has shot up 30-fold in the past 50 years. The cumulative dengue diseases burden has attained an unprecedented proportion in recent times with a sharp increase in the size of human population at risk. Dengue disease presents highly complex pathophysiological, economic, and ecologic problems.Citation37 One billion people (15% of the world’s population) reside in India. India’s population is twice that of Southeast Asia, the region that currently reports the most dengue-related deaths. A recent study done at the University of Oxford using a map-based approach to model how many dengue cases were occurring in various parts of the world, estimated that India had the largest number of dengue cases, with about 33 million apparent and another 100 million asymptomatic infections occurring annually.Citation38
Quantifying the burden of dengue is critical for policy makers to set policy priorities and make informed decisions about disease control. Surveillance for dengue has been very limited in India, and reporting to the central government has also not been mandatory. In 2004, a World Health Organization initiative called for promoting improvement of dengue surveillance as part of the Integrated Disease Surveillance Programme in India, strengthening laboratory networking and quality assurance, and reviewing case definitions.Citation39 Although improvements are being made, the current gaps in epidemiological data and surveillance mean that the burden of dengue in India probably is much higher.
Pathogenesis of dengue
Replication of the dengue virus occurs within mononuclear cells including skin dendritic cells, tissue macrophages, peripheral blood monocytes, and hepatocytes. At present, the host cell receptors involved in the viral entry are mostly unknown.Citation40 Primary or first infection in nonimmune persons usually causes DF. Subsequent dengue infection by a different serotype causes more severe illness, such as DHF/DSS. The key manifestations of DHF/DSS are sudden onset of shock, capillary leakage, and hemorrhagic diathesis/thrombocytopenia occurring at the time of defervescence of fever. Pathogenesis is not well-defined, but it is suggested that during secondary infection with a different serotype, cross-reactive nonneutralizing antibodies bind to DENV and facilitate uptake via Fc receptors, resulting in enhanced viral replication. The resultant higher viral antigen load leads to an exaggerated activation of cross-reactive dengue specific T cells. Biological mediators released by the activated T cells as well as virus-infected cells along with complement activation by viral proteins and immune complexes are implicated in increasing vascular permeability and coagulopathy.Citation41 This phenomenon is known as antibody-dependent enhancement.
Dengue case definition
Earlier guidelines classified dengue into three categories: DF, an acute febrile illness; DHF (grades 1 and 2), a syndrome characterized by increased vascular permeability; and altered hemostasis that may progress to hypovolemic shock known as DSS (grades 3 and 4).Citation42 The new revised clinical classification of dengue cases now divides the clinical cases into two categories: dengue with or without warning signs, and severe dengue infection ().Citation43
Diagnosis of dengue virus infection
Laboratory diagnosis of dengue is routinely done by demonstration of antidengue immunoglobulin M (IgM) antibodies or by nonstructural protein 1(NS-1) antigen in patients’ serum/plasma depending upon day of illness using either enzyme-linked immunosorbent assay (ELISA) or immune chromatographic-based rapid card tests (). Rising titer of dengue immunoglobulin G (IgG) antibody can also be used for the diagnosis. Virus isolation techniques are very specific but rarely used due to increased complexity and the time taken to obtain results. The Aedes albopictus (A. albopictus) mosquito C6/36 cell line is the method of choice for virus isolation, although other mosquito and mammalian cell lines (such as Aedes pseudoscutellaris, Vero and LLC-MK2 cells) can also be used. Molecular methods such as reverse transcriptase polymerase chain reaction (RT-PCR) or real time polymerase chain reaction (qRT-PCR) are being increasingly used in diagnosis. A single tube nested PCR with primers directed against serotype specific regions of the viral is routinely used for typing of the virus.Citation44
Treatment of dengue virus infection
Currently, no effective antiviral agents to treat dengue infection are available. The management of dengue virus infection is essentially supportive and symptomatic. Intravenous rehydration is the therapy of choice; this intervention can reduce the case fatality rate to less than 1% of severe cases. The dynamic nature of dengue demands close monitoring and repeated clinical and laboratory evaluations. A rapid response to platelet and fresh frozen plasma and cryoprecipitate transfusion is seen.Citation45
Prevention of dengue
Vector control
With limited therapeutic strategies and the current lack of a vaccine, effective vector control methods are an essential component to reduce dengue-related mortality and morbidity. A. aegypti is the most common vector of dengue in India, followed by A. albopictus. Water-holding containers, eg, plastic, metal drums, and cement tanks facilitate breeding of Ae. aegypti. Vector control methods involve environmental, chemical, and biological management approaches. Utilizing an effective integrated vector control strategy with a combination of approaches, such as social mobilization and integration of chemical and nonchemical vector control methods targeting areas of high human–vector contact, will aid in reducing dengue transmission. The evolution and spread of resistance to insecticides is a growing concern for the control of dengue vectors. Bioassay data demonstrate that resistance to organophosphates (temephos) and pyrethroids is widespread in A. aegypti, and resistance has also been reported in A. albopictus.Citation46 Monitoring resistance is, therefore, necessary to ensure that effective insecticides are being used. The National Vector Borne Disease Control Program has been initiated to control the emerging threat by vector-borne diseases in India. Despite extensive efforts in developing the effective dengue control measures, several factors pose difficulties in implementing efficient vector control measures, such as large population size, lack of awareness, lack of education, and poverty.
Integrated surveillance
Surveillance is an essential component of any dengue prevention and control program, as it provides the necessary information for risk assessment and program guidance. Surveillance utilizes both passive and active data collection methodologies. Laboratory support is a critical component in any kind of surveillance.Citation47,Citation48 The laboratory should be able to identify not only the presence of the dengue virus but also its serotype and to correlate these to the severity of illness and whether the patients are experiencing a primary or secondary dengue infection. Furthermore, information on the genetic sequence of the circulating viruses, both during and between dengue epidemics, would be of great value to predict epidemics. In India, the government’s initiativeCitation49 to set up virology diagnostic laboratories in different states along with initiation of a national program has geared up the surveillance activities; however, a lot more remains to be achieved for effective surveillance.
Toward a new vaccine
To date, an effective vaccine to protect against dengue is lacking owing to several challenges such as the requirement of a tetravalent vaccine providing long-term homotypic and heterotypic protection, the lack of an adequate animal disease model, and the resulting uncertainty around correlates of protection. However, several candidate vaccines are in various phases of trials. The ideal dengue vaccine should be free of important reactogenicity, induce life-long protection against infection with any of the four DENV serotypes, and be affordable. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on the chimeric yellow fever-dengue virus, has progressed to phase III efficacy studies.Citation50 The safety and clinical efficacy of the chimeric yellow fever-dengue virus have so far shown promising results.Citation51 Several other vaccine candidates like live-attenuated, subunit, deoxyribonucleic acid(DNA) and purified inactivated vaccines, are at earlier stages of clinical development. Additional technological approaches, such as virus-vectored and virus-like particle–based vaccines, are under evaluation in preclinical studies.
Conclusion
Dengue in India has established its roots. Now it is endemic and almost hyperendemic in our population. National level comprehensive studies to estimate the true burden of dengue in India and its geographical mapping are lacking. Through integrated and combined efforts from various sectors and policy makers, prevention of dengue must be intensified to control further disease transmission.
Disclosure
The authors report no conflicts of interest in this work.
References
- GublerDJThe changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?Comp Immunol Microbiol Infect Dis20042731933015225982
- GuptaEDarLKapoorGBroorSThe changing epidemiology of dengue in Delhi, IndiaVirol J20063929617083743
- GuptaNSrivastavaSJainAChaturvediUCDengue in IndiaIndian J of Med Res201213637339023041731
- ChakravartiAMatlaniMKashyapBKumarAAwareness of changing trends in epidemiology of dengue fever is essential for epidemiological surveillanceIndian J Med Res201230222226
- ChaturvediUCNagarRDengue and dengue haemorrhagic fever: Indian perspectiveJ Biosci20083342944119208969
- SarkarJKChatterjeeSNChakravartySKHaemorrhagic fever in Calcutta: some epidemiological observationsIndian J Med Res19645265165914195505
- ChatterjeeSNChakravartiSKMitraACSarkarJKVirological investigation of cases with neurological complications during the outbreak of haemorrhagic fever in CalcuttaJ Indian Med Assoc1965453143165832545
- PrabhakarHMathewPMarshallaRAryaMDengue haemorrhagic fever outbreak in October-November 1996 in Ludhiana, Punjab, IndiaIndian J Med Res1997106139248206
- AggarwalAChandraJAnejaSPatwariAKDuttaAKAn epidemic of dengue hemorrhagic fever and dengue shock syndrome in children in DelhiIndian Pediatr19983572773210216566
- DarLBroorSSenguptaSXessISethPThe first major outbreak of dengue hemorrhagic fever in Delhi, IndiaEmerg Infect Dis1999558959010458971
- AgarwalRKapoorSNagarRA clinical study of the patients with dengue hemorrhagic fever during the epidemic of 1996 at Lucknow, IndiaSoutheast Asian J Trop Med Public Health19993073574010928368
- GuptaEDarLNarangPSrivastavaVKBroorSSerodiagnosis of dengue during outbreak at a tertiary care hospital in DelhiIndian J Med Res2005121363815713977
- DashPKSaxenaPAbhyankarABhargavaRJanaAMEmergence of dengue virus type-3 in northern IndiaSoutheast Asian J Trop Med Public Health20053637037715916043
- DarLGuptaENarangPBroorSCocirculation of dengue serotypes, Delhi, India, 2003Emerg Infect Dis20061235235317080580
- WahalaWMSilvaAMThe human antibody response to dengue virus infectionViruses201132374239522355444
- KaramchandaniPVDengue group of fevers in IndiaLancet1946163869221011278
- RamakrishananSPGelfandHMBosePNSehgalPNMukharjeeRNThe epidemic of acute haemorrhagic fever, Calcutta: epidemiological inquiryIndian J Med Res19645263365014195504
- SarkarJKPavriKMChatterjeeSNChakravartySKAndersonCRVirological and serological studies of cases of haemorrhagic fever in CalcuttaIndian J Med Res19645268469114195508
- BalayaSPaulSDD’LimaLVPavriKMInvestigations on an outbreak of dengue in Delhi in 1967Indian J Med Res1969577677745805380
- GhoshBNA study on the epidemic of dengue-like fever in Pondicherry (1964–65 and 1965–66)J Indian Med Assoc1968512612645706900
- MyersRMVarkeyMJReubenRJesudassESDengue outbreak in Vellore, southern India, in 1968, with isolation of four dengue types from man and mosquitoesIndian J Med Res19705824305439947
- SinghUBMaitraABroorSRaiAPashaSTSethPPartial nucleotide sequencing and molecular evolution of epidemic causing dengue 2 strainsJ Infect Dis199918095996510479118
- DashPKParidaMMSaxenaPEmergence and continued circulation of dengue-2 (genotype IV) virus strains in northern IndiaJ Med Virol20047431432215332281
- VajpayeeMMohankumarKWaliJPDarLSethPBroorSDengue virus infection during post-epidemic period in Delhi, IndiaSoutheast Asian J Trop Med Public Health19993050751010774660
- MyersRMCareyDEConcurrent isolation from patient of two arboviruses, Chikungunya and dengue type 2Science1967157130713086038994
- MyersRMVarkeyMJReubenRJesudassESDengue. outbreak in Vellore, southern India, in 1968, with isolation of four dengue types from man and mosquitoesIndian J Med Res19705824305439947
- ChaturvediUCMathurAMehrotraRMExperimentally produced cardiac injury following dengue virus infectionIndian J Pathol Bacteriol1974172182204457475
- KumarASharmaSKPadbidriVSThakareJPJainDCDattaKKAn outbreak of dengue fever in rural areas of northern IndiaJ Commun Dis20013327428112561505
- ParidaMMDashPKUpadhyayCSaxenaPJanaAMSerological and virological investigation of an outbreak of dengue fever in Gwalior, IndiaIndian J Med Res200211624825412807151
- MatlaniMChakravartiAChanging trends of dengue disease: a brief report from a tertiary care hospital in New DelhiBraz J Infect Dis20111518418521503411
- DayarajCKakadeMBBhagatABDetection of dengue-4 virus in Pune, western India after an absence of 30 years – its association with two severe casesVirol J20118464921284832
- GuptaEMohanSBajpaiMChoudharyASinghGCirculation of Dengue virus-1 (DENV-1) serotype in Delhi, during 2010–11 after Dengue virus-3 (DENV-3) predominance: a single centre hospital-based studyJ Vector Borne Dis201249828522898479
- MishraGJainAPrakashOMolecular characterization of dengue viruses circulating during 2009–2012 in Uttar Pradesh, IndiaJ Med Virol Epub622014
- DashAPBhatiaRKalraNLDengue in South-East Asia: an appraisal of case management and vector controlWorld Health OrganizationDengue Bulletin36GenevaWorld Health Organization2012113 Available from: http://www.wpro.who.int/mvp/epidemiology/dengue/Dengue_Bulletin_Vol36.pdfAccessed August 29, 2014
- BharajPChaharHSPandeyAConcurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, IndiaVirol J20085118182120
- GuptaEDarLBroorSConcurrent infection by two dengue virus serotypes among dengue patientsIndian J Med Microbiol20082640240318974508
- GublerDJThe economic burden of dengueAm J Trop Med Hyg20128674374422556068
- BhattSGethingPWBradyOJThe global distribution and burden of dengueNature201349650450723563266
- Integrated Disease Surveillance Project (IDSP) Training Manual for Medical Officers for Hospital Based Disease Surveillance National Centre for Disease Control (NCDC) http://idsp.nic.in/idsp/IDSP/MedOff.pdfAccessed on 29.08.14
- JessieKFongMYDeviSLamSKWongKTLocalization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridizationJ Infect Dis20041891411141815073678
- HalsteadSBAntibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascadeRev Infect Dis198911Suppl 4S830S8392665015
- World Health OrganizationClinical diagnosisDengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control2nd edGenevaWorld Health Organization19971233 Available from: http://www.who.int/csr/resources/publications/dengue/012-23.pdfAccessed August 29, 2014
- World Health Organization and the Special Programme for Research and Training in Tropical DiseasesDengue: Guidelines for Diagnosis, Treatment, Prevention and Control New editionGenevaWorld Health Organization2009 Available from: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdfAccessed August 29, 2014
- LanciottiRSCalisherCHGublerDJChangGJVorndamAVRapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reactionJ Clin Microbiol1992305455511372617
- ChaudharyRKhetanDSinhaSTransfusion support to Dengue patients in a hospital based blood transfusion service in north IndiaTransfus Apher Sci20063523924417097349
- RansonHBurhaniJLumjuanNBlackWCIVInsecticide resistance in dengue vectorsTropIKA Reviews201011 Available from: http://journal.tropika.net/scielo.php?script=sci_arttext&pid=s2078-86062010000100003&lng=enAccessed August 29, 2014
- Rigau-PerezJGGublerDJSurveillance for dengue and dengue hemorrhagic feverGublerDJKunoGDengue and Dengue Hemorrhagic FeverOxfordCAB International1997405424
- World Health OrganizationGlobal Strategy for Dengue Prevention and Control 2012–2020GenevaWorld Health Organization2012 Available from: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdfAccessed August 29, 2014
- Department of health and research, New Delhi 12th plan document Available from: http://icmr.nic.in/Publications/plan/ICMR%20XIIth%20Plan%20(2012-2017).pdfAccessed November 12, 2014
- ThisyakornUThisyakornCLatest developments and future directions in dengue vaccinesTher Adv Vaccines2014213924757522
- CapedingMRTranNHHadinegoroSRCYD14 Study GroupClinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trialLancet Epub7102014